Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. OvermanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: [email protected]Ray McDermottSt Vincent's University Hospital and Cancer Trials Ireland, Dublin, IrelandJoseph L. LeachAllina Health System, Minneapolis, MN, USASara LonardiIstituto Oncologico Veneto IOV-IRCSS, Padova, ItalyHeinz‐Josef LenzUSC Norris Comprehensive Cancer Center, Los Angeles, CA, USAMichael A. MorseDuke University Medical Center, Durham, NC, USAJayesh DesaiRoyal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, AustraliaAndrew HillTasman Oncology Research Ltd, Southport, Queensland, QLD, AustraliaMichael D. AxelsonBristol-Myers Squibb, Princeton, NJ, USARebecca A. MossBristol-Myers Squibb, Princeton, NJ, USAMonica V. GoldbergBristol-Myers Squibb, Princeton, NJ, USAZ. Alexander CaoBristol-Myers Squibb, Princeton, NJ, USAJean-Marie LedeineBristol-Myers Squibb, Braine-L'Alleud, BelgiumGregory A. MaglinteBristol-Myers Squibb, Princeton, NJ, USAScott KopetzThe University of Texas MD Anderson Cancer Center, Houston, TX, USAThierry AndréHôpital Saint-Antoine
2017en
Ochiq kirishYashil
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba